SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-207640"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-207640" > Outcomes of apixaba...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003557naa a2200493 4500
001oai:DiVA.org:uu-207640
003SwePub
008130917s2013 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2076402 URI
0247 a https://doi.org/10.1093/eurheartj/eht1352 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Al-Khatib, Sana M.4 aut
2451 0a Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation :b results from the ARISTOTLE trial
264 c 2013-04-17
264 1b Oxford University Press (OUP),c 2013
338 a print2 rdacarrier
520 a It is uncertain whether the benefit from apixaban varies by type and duration of atrial fibrillation (AF). A total of 18 201 patients with AF [2786 (15.3) with paroxysmal and 15 412 (84.7) with persistent or permanent] were randomized to apixaban or warfarin. In this pre-specified secondary analysis, we compared outcomes and treatment effect of apixaban vs. warfarin by AF type and duration. The primary efficacy endpoint was a composite of ischaemic or haemorrhagic stroke or systemic embolism. The secondary efficacy endpoint was all-cause mortality. There was a consistent reduction in stroke or systemic embolism (P for interaction 0.71), all-cause mortality (P for interaction 0.75), and major bleeding (P for interaction 0.50) with apixaban compared with warfarin for both AF types. Apixaban was superior to warfarin in all studied endpoints, regardless of AF duration at study entry (P for all interactions 0.13). The rate of stroke or systemic embolism was significantly higher in patients with persistent or permanent AF than patients with paroxysmal AF (1.52 vs. 0.98; P 0.003, adjusted P 0.015). There was also a trend towards higher mortality in patients with persistent or permanent AF (3.90 vs. 2.81; P 0.0002, adjusted P 0.066). The risks of stroke, mortality, and major bleeding were lower with apixaban than warfarin regardless of AF type and duration. Although the risk of stroke or systemic embolism was lower in paroxysmal than persistent or permanent AF, apixaban is an attractive alternative to warfarin in patients with AF and at least one other risk factor for stroke, regardless of the type or duration of AF.
653 a Paroxysmal atrial fibrillation
653 a Persistent atrial fibrillation
653 a Permanent atrial fibrillation
653 a Apixaban
653 a Stroke
653 a Major bleeding
7001 a Thomas, Laine4 aut
7001 a Wallentin, Larsu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)larswall
7001 a Lopes, Renato D.4 aut
7001 a Gersh, Bernard4 aut
7001 a Garcia, David4 aut
7001 a Ezekowitz, Justin4 aut
7001 a Alings, Marco4 aut
7001 a Yang, Hongqui4 aut
7001 a Alexander, John H.4 aut
7001 a Flaker, Gregory4 aut
7001 a Hanna, Michael4 aut
7001 a Granger, Christopher B.4 aut
7102 a Uppsala universitetb Uppsala kliniska forskningscentrum (UCR)4 org
7730 t European Heart Journald : Oxford University Press (OUP)g 34:31, s. 2464-2471q 34:31<2464-2471x 0195-668Xx 1522-9645
8564 u https://academic.oup.com/eurheartj/article-pdf/34/31/2464/17896031/eht135.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-207640
8564 8u https://doi.org/10.1093/eurheartj/eht135

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy